ArticleCommunications biology2024
E. coli and S. aureus resist silver nanoparticles via an identical mechanism, but through different pathways.
Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Effect of Silver Nanoparticle Addition on the Antimicrobial Properties of Poly(methyl methacrylate) Used for Fabrication of Dental Appliances: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- PhytoSynthesized Nano-Zinc Formulation for Sustainable Growth and Yield Enhancement in Tomatoes Under Protected Cultivation.Plants (Basel, Switzerland) · 2026Article
- Fungal-Based Biogenic Silver Nanoparticles: Synthesis, Mathematical Modeling and Application.Molecules (Basel, Switzerland) · 2026Article
- Antimicrobial Surfaces for Reusable Food Packaging: A Comprehensive Review of Functionality and Suitability.Comprehensive reviews in food science and food safety · 2026Review
- Bacterial Adaptive Responses to Green and Chemically Synthesized Silver Nanoparticles: Implications for Resistance Development.Nanomaterials (Basel, Switzerland) · 2026Article
- Green-Synthesized vs. Chemical Silver Nanoparticles: A Comparative Study onMicroorganisms · 2026Article
- Bioinformatic Resistome Profiling of Metal Tolerance Mechanisms in Endodontic Infections: Implications for Antimicrobial Nanoparticle-Based Biomaterials.Journal of functional biomaterials · 2026Article
- Harnessing the Antimicrobial Potential of Baicalein-Coated FeACS applied materials & interfaces · 2026Article
- Article
- Multidrug Resistance and Adaptive Response to Silver and Gold Nanoparticles in Methicillin-ResistantPathogens (Basel, Switzerland) · 2026Article
- Zinc-Based Nanoparticles Reduce the Bacterial Burden and Protect Collagen in a Mouse Cutaneous Wound Model.ACS omega · 2026Article
- Nanocellulose hydrogels as bio-interface analogs for studying nanomaterial transport and accumulation.bioRxiv : the preprint server for biology · 2026Article
- Eco-Friendly In Situ Fabrication of Silver Nanoparticle-Loaded Chitosan Nanogels for Antibacterial Applications.Gels (Basel, Switzerland) · 2026Article
- Article
- Emerging strategies of bacterial adaptation mechanisms to silver and metal oxide nanomaterials.FEMS microbiology reviews · 2026Review
- Green synthesis of silver nanoparticles usingFrontiers in pharmacology · 2026Article
- Nanomedicine against antimicrobial resistance: mechanistic insights and next-generation therapeutic potential.Frontiers in chemistry · 2026Review
- Breaking the biofilm barrier: herbomineral nanocomposites to controlFrontiers in chemistry · 2026Article
- Combating Foodborne MRSA: Identification and Silver Nanoparticle-Based Antibacterial Strategies with Antibiotic Synergy and Resistance Evolution Assessment.Microorganisms · 2025Article
- Sustainable production of silver chloride nanoparticles from desert flora for biomedical applications with multifunctional biological activities.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Nanostructured materials with antibacterial activity face the same threat as conventional antibiotics - bacterial resistance, which reduces their effectiveness. However, unlike antibiotics, research into the emergence and mechanisms of bacterial resistance to antibacterial nanomaterials is still in its early stages. Here we show how Gram-positive Staphylococcus aureus and Gram-negative Escherichia coli bacteria develop resistance to silver nanoparticles, resulting in an increase in the minimum inhibitory concentration from 1.69 mg/L for S. aureus and 3.38 mg/L for E. coli to 54 mg/L with repeated exposure over 12 and 6 cultivation steps, respectively. The mechanism of resistance is the same for both types of bacteria and involves the aggregation of silver nanoparticles leading to the formation of black precipitates. However, the way in which Gram-positive and Gram-negative bacteria induce aggregation of silver nanoparticles is completely different. Chemical analysis of the surface of the silver precipitates shows that aggregation is triggered by flagellin production in E. coli and by bacterial biofilm formation in S. aureus. However, resistance in both types of bacteria can be overcome by using pomegranate rind extract, which inhibits both flagellin and biofilm production, or by stabilizing the silver nanoparticles by covalently binding them to a composite material containing graphene sheets, which protects the silver nanoparticles from aggregation induced by the bacterial biofilm produced by S. aureus. This research improves the understanding of bacterial resistance mechanisms to nanostructured materials, which differ from resistance mechanisms to conventional antibiotics, and provides potential strategies to combat bacterial resistance and develop more effective antimicrobial treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.